Literature DB >> 24643717

In reply.

Daniel J Lenihan1, Peter R Kowey.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24643717      PMCID： PMC3958469          DOI： 10.1634/theoncologist.2013-0433

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  4 in total

Review 1.  Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

Authors:  Daniel J Lenihan; Peter R Kowey
Journal:  Oncologist       Date:  2013-08-05

2.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

3.  Nilotinib-associated vascular events.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-24

4.  Pulmonary arterial hypertension in patients treated by dasatinib.

Authors:  David Montani; Emmanuel Bergot; Sven Günther; Laurent Savale; Anne Bergeron; Arnaud Bourdin; Helene Bouvaist; Matthieu Canuet; Christophe Pison; Margareth Macro; Patrice Poubeau; Barbara Girerd; Delphine Natali; Christophe Guignabert; Frédéric Perros; Dermot S O'Callaghan; Xavier Jaïs; Pascale Tubert-Bitter; Gérard Zalcman; Olivier Sitbon; Gérald Simonneau; Marc Humbert
Journal:  Circulation       Date:  2012-03-26       Impact factor: 29.690
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.